FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 464 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR How Having a Creative Outlet Helped Me Cope During Cancer November 8, 2022 EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin June 12, 2025 The Switch of Breast Tumours to HER2-Low Status in Recurrence Might... May 8, 2021 EMA Recommends Granting a Marketing Authorisation for Retifanlimab February 26, 2024 Load more HOT NEWS How I Navigated Being a Young Mom During Cancer: A Survivor’s... Efficacy of Sunitinib in Patients with Metastatic Phaeochromocytomas and Paragangliomas Hamlet Drug, Modeled After Protein In Breast Milk, Kills Tumor Cells... 3-Year-Old Boy Receives Hundreds Of Sweet Birthday Cards In The Mail...
